BusinessWire India
Hyderabad (Telangana) [India], February 5: GV Safety Assessment Platform (GVSAP), an integrated preclinical R&D enabler within the GVRP portfolio, today announced an expansion of its strategic collaboration with Biocytogen (SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. This move significantly bolsters access to advanced biomedical research tools for India's burgeoning biopharma ecosystem.
Building on their existing partnership, which already provides Indian researchers with Biocytogen's BioMiceTM humanized and engineered research models, the expanded alliance now incorporates pharmacology services, gene-edited cell line licensing, and distribution. This broadens support for translational and discovery-stage research, enabling seamless workflows from target validation to functional and pharmacological evaluation.
Key enhancements include:
- Streamlined pharmacology services: Access to Biocytogen's expertise in in vivo efficacy studies using advanced BioMice™ models.
- Cell line licensing and distribution: Access to a comprehensive library of off-the-shelf, gene-edited reporter and stable cell lines that significantly accelerate preclinical screening workflows by eliminating months of development time, supporting the strategic collaboration with GVSAP to advance biopharmaceutical innovation in the Indian market.
- Integrated portfolio: Complements off-the-shelf humanized mouse models and gene editing services, fostering end-to-end preclinical programs aligned with global standards.
Headquartered in Genome Valley, Hyderabad, GVSAP operates AAALAC International-accredited and OECD-GLP-compliant facilities spanning over 35,000 square feet. Its state-of-the-art vivarium includes dedicated SPF breeding and preclinical testing areas, upholding rigorous standards in research integrity, biosafety, and animal welfare.
Kalyan Korisapati, Co-Founder & CEO of GV Research Platform, commented: "Our deepened collaboration with Biocytogen underscores our commitment to elevating translational research in India. By adding pharmacology services and cell line access, we empower researchers with integrated, precision-driven tools to accelerate drug discovery amid India's rising R&D investments."
Yuelei Shen, CEO of Biocytogen, added: "India's biopharma sector is evolving rapidly, with increasing demand for reliable, cutting-edge solutions. Partnering with GVSAP brings our BioMiceTM humanized mouse models, gene-edited cell lines, and pharmacology capabilities directly to Indian innovators--driving faster therapeutic breakthroughs."
This alliance advances both organizations' vision of democratizing advanced research technologies, positioning India as a global hub for preclinical innovation and supporting the next wave of therapeutics development.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same)